Summary

Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):e2021818118. doi: 10.1073/pnas.2021818118.

Involvement of cytotoxic Eomes-expressing CD4(+) T cells in secondary progressive multiple sclerosis.

Abstract:

Multiple sclerosis (MS), a putative autoimmune disease of the central nervous system (CNS), commonly presents as relapsing-remitting MS (RRMS), characterized by recurrent episodes of peripheral disabling symptoms resulting from inflammatory CNS damage. Many RRMS patients transition to a chronic disease course with progressive neurological dysfunctions (secondary progressive MS, SPMS), with the progression rate varying between patients and over time. SPMS pathogenesis is now linked to immune-cell-mediated processes, although the mechanisms driving SPMS transition and progression remain elusive, and SPMS lacks biomarkers and effective treatments. We report the crucial involvement of cytotoxic CD4+ T cells expressing Eomes (Eomes+ Th cells) in SPMS pathogenesis-a Th cell subset previously identified in a mouse model of late/chronic autoimmune CNS inflammation. Few Eomes+ Th cells circulate in RRMS patient peripheral blood (n = 44), primary progressive MS (PPMS) patients (n = 25), or healthy controls (n = 42), but Eomes+ Th cells were significantly increased in SPMS (n = 105, P < 0.0001). Strikingly, lymphocytes isolated from SPMS autopsy brain samples revealed CD4+ T cells infiltrating CNS that coexpressed Eomes and the cytotoxic molecule granzyme B. In particular, the Eomes+ Th cell levels were increased in SPMS patients in progressive disease phases versus SPMS patients without current disability increases (P < 0.0001). Moreover, Eomes level acted as a biomarker to predict SPMS patients at risk of disease worsening with over 80% accuracy (ROC-AUC = 0.8276). Overall, our results indicate that granzyme B-expressing Eomes+ T helper cells are involved in the pathogenesis of SPMS, with significant implications for SPMS biomarkers and therapeutic targets.

日本語要旨:

MS患者の20-50%は、難治性で障害の大きい二次進行型多発性硬化症(SPMS)へ移行するが、その診断は臨床的な評価に頼るしかなく、診断・治療の遅れが生じていた。今回、免疫応答に関わるT細胞の一種であるEomes陽性Th細胞(エオメス陽性ヘルパーT細胞)がSPMSの診断や病勢評価において有用なバイオマーカーとなることを明らかにした。今後、SPMS診断能力の向上、ひいてはMS患者の予後の向上に大きく貢献することが期待される。

PMID:  33836594

前ページへ戻る

PAGE TOP